In both human hepatoma cell line HepG2 and in the mouse liver, Yang and colleagues found that the rmIL-22 could strongly activate STAT3 signaling, depending on the STAT3-binding tyrosine residues in IL-22R1 [25]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.